Progenics is a nasdaq company, with a nasdaq CEO,

Progenics is a nasdaq company, with a nasdaq CEO, but here we are with leronlimab and not them. Go back to 2012, replace NP with any other CEO you want, any, I believe 100% mono would not have happened. Possibly not even combo, since NP talked the FDA into accepting mono safety data. Does that give NP an excuse on over-promising, no. Should he be getting 1.5M, no. Does part of his salary go to stock? Yes he does, 40%. If NP doesn't deliver the BLA by the end of year, he is probably done. People imo should give NP to the end of the year to finish the BLA, get the licensing done. If he can't make that, then fine move on. But I accept the path that got us here must have started with NP as CEO, not a seasoned CEO, who would have never taken a change on leronlimab to begin with. Would have never pushed on mono, might have given up on combo as both Progenics and Maddon apparently did. Am I attached to NP, no, I'm here for leronlimab, but I would actual be a little nervous with switching now as most pre-revenue biotech CEOs have no problem with killing their original shareholders, probably why there is still so many people still around able to complain here but not in the others that have their original holders in the dust. So here we are with the good, the bad, and the ugly.